Enfusion - Competitors and Alternatives

Enfusion’s front-to-back-office software covers a wide set of functionality, covering features from order raising to shadow NAV. It was initially built for hedge funds.

A natural strength of Enfusion is its end-to-end workflows across the full investment lifecycle. This is thanks to most functions being covered in the single system. The system’s core architecture is multi-tenant.

In this section, you can select between five alternatives to Enfusion you might want to consider and learn more about them.

Enfusion pricing isn't publicly available at this time.

In April 2025, Clearwater Analytics (CWAN) acquired Enfusion (ENFN). The merger is of two American ,publicly listed companies that have been focused on different segments of the buy-side (asset owners for Clearwater Analytics and Hedge Funds for Enfusion). Time will tell what the merger will mean for clients.

The team behind Limina are former investment managers, both at hedge funds, asset owners and asset management firms. We’ve not just faced the heat of the markets - but also the challenges of selecting the right investment management platform. Having been in your shoes, we've created our entire website to help your system selection process.

Limina is a web-based investment management platform that is often a powerful alternative to Enfusion's investment management platform. If you’d like to learn more about Limina, here are some resources that you might find helpful:

• Which type of firm Limina IMS fits best
• Which type of firm Limina IMS might not be suited for
• Limina IMS product overview

Bloomberg AIM (part of Bloomberg buy-side solutions and PMGO) is an order management system (OMS) that competes with Enfusion. It provides a suite of capabilities for rebalancing, pre-trade compliance, and post-trade processing.

AIM is embedded in the Bloomberg Terminal, which means it connects to market data (pricing etc) readily available to terminal users. It's less common to use Bloomberg's order management system together with data sources or execution management systems from other vendors.

AIM integrates with other Bloomberg products (such as TCA & risk analytics), and such integrations are also possible for other providers (such as Enfusion and Limina).

Paladyne was acquired by Broadridge in 2011, just six years after its founding. It built and delivered a solution primarily to hedge funds, similar in scope to Enfusion. 

Broadridge has since rebranded the offering at least once, and it's not apparent from online sources what product is available for new clients nowadays.

Explore more competitors to Paladyne Portfolio Management System.

Charles River Investment Management System (CRIMS) is a strong platform, especially for the Front Office. It's both a sophisticated order management system (OMS) and execution management system (EMS). Compared to Enfusion software, it's generally used by larger investment managers.

The execution management system connects to trade venues and liquidity providers for effective execution.

The platform is used by some of the largest asset managers in the world.

SS&C has many products that could compete with Enfusion (and themselves at times). The first is Eze OMS (Order Management System) and Tradar (Portfolio Accounting), two products initially created to service hedge funds. Eze OMS and Tradar have been integrated with realtick (Eze’s EMS) to create the Eze Investment Suite.

In 2018, SS&C acquired Eze Software from TPG for $1.45 billion. SS&C already owned Advent, which has solutions that partly overlap with Eze. Nowadays, there is also a solution called Aloha available from SS&C, and they have a web-based tool called Ecplise.

From online sources, it appears unclear which respective product is suited for which type of investment manager or use case.